Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Sep 18, 2022 10:08am
174 Views
Post# 34969766

RE:RE:Every time you hear a cricket sound

RE:RE:Every time you hear a cricket sound
Inthepez wrote:

LOL!

What do you get out of your comments? Are you looking for attention? 

 

Stutters wrote:
thats the sound of an insider selling his shares for pennies on the dollar

 

 




Stage is set - the P2 show  is about to start (~ Sept 28).
Pregame might include a CITA close and commercial study but the timing is up in the air.
It's all about the confidence in where acute dosing may take us.

I predict that if we can get acute, we quickly get the attention of chronic pain specialists (let's just call it flare-ups) and then we get the attention of cancer specialists (let's just call it FAP - even though we'll learn really quickly what 346 can do for colon cancer as our drug rides down the canal of forbidden love).

As we talk more and more about chronic - I'm going to be lumping all specialists into that "chronic" group.  I am also referencing the idea of "strict regimen control" when I say "chronic" and the need for specialists to administer base on a strict control.  Leaving nothing to chance here as people who exhibit higher enzyme levels need to be dealt with quickly and in a proactive manner.

Early days friends - the path is long.
We've been training a lifetime for this moment. 
Had a few engine leaks and a few postponed launches.
Our team ripped apart those engines and rebuilt them with better understanding.

They think they've figured it out.  Let's see how fast we can take this thing !!!

:  )


Love this game - it's just the suspense and the unknown I can do without - hahaha
<< Previous
Bullboard Posts
Next >>